| scholarly article | Q13442814 |
| P50 | author | Lance A. Liotta | Q74243861 |
| P2093 | author name string | Emanuel F Petricoin | |
| P2860 | cites work | Differential exoprotease activities confer tumor-specific serum peptidome patterns | Q33230965 |
| Lessons from Kitty Hawk: from feasibility to routine clinical use for the field of proteomic pattern diagnostics | Q40493491 | ||
| Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? | Q40572496 | ||
| Serum proteomic patterns for detection of prostate cancer | Q40627138 | ||
| Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. | Q50749101 | ||
| Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer | Q63446333 | ||
| An investigation into the human serum "interactome" | Q24294835 | ||
| Analysis of albumin-associated peptides and proteins from ovarian cancer patients | Q24314877 | ||
| A data review and re-assessment of ovarian cancer serum proteomic profiling | Q24806513 | ||
| Clinical proteomics: Written in blood | Q28213537 | ||
| Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer | Q28216062 | ||
| The human plasma proteome: history, character, and diagnostic prospects | Q28218148 | ||
| Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse | Q29620396 | ||
| Use of proteomic patterns in serum to identify ovarian cancer | Q30819686 | ||
| Importance of communication between producers and consumers of publicly available experimental data | Q30982896 | ||
| Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. | Q31093356 | ||
| Characterization of the low molecular weight human serum proteome | Q31153810 | ||
| Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry | Q33199436 | ||
| A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis | Q33212616 | ||
| High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures | Q33221138 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 26-30 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold | |
| P478 | volume | 116 |
| Q34215634 | A novel peptidomics approach to detect markers of Alzheimer's disease in cerebrospinal fluid |
| Q48012382 | A rapid differential display analysis of nasal swab fingerprints to distinguish allergic from non-allergic rhinitis subjects by mesoporous silica particles and MALDI-TOF mass spectrometry |
| Q33564901 | Analysis of post-operative changes in serum protein expression profiles from colorectal cancer patients by MALDI-TOF mass spectrometry: a pilot methodological study |
| Q35196711 | Analysis of the differences of serum protein mass spectrometry in patients with triple negative breast cancer and non-triple negative breast cancer |
| Q34420715 | Analysis of the differentially expressed low molecular weight peptides in human serum via an N-terminal isotope labeling technique combining nano-liquid chromatography/matrix-assisted laser desorption/ionization mass spectrometry |
| Q37593989 | Approaching clinical proteomics: current state and future fields of application in cellular proteomics |
| Q33467523 | Approaching clinical proteomics: current state and future fields of application in fluid proteomics |
| Q33829971 | Association between plasma proteome profiles analysed by mass spectrometry, a lymphocyte-based DNA-break repair assay and radiotherapy-induced acute mucosal reaction in head and neck cancer patients |
| Q33292219 | Biomarker discovery in infectious diseases using SELDI. |
| Q37025534 | Calorimetric analysis of the plasma proteome |
| Q37095300 | Calorimetric analysis of the plasma proteome: identification of type 1 diabetes patients with early renal function decline |
| Q36402223 | Calorimetry outside the box: a new window into the plasma proteome. |
| Q34489436 | Capture, enrichment, and mass spectrometric detection of low-molecular-weight biomarkers with nanoporous silicon microparticles |
| Q33520447 | Challenges for biomarker discovery in body fluids using SELDI-TOF-MS. |
| Q46340998 | Characterization of the Low-Molecular-Weight Human Plasma Peptidome. |
| Q36242482 | Chronological Profiling of Plasma Native Peptides after Hepatectomy in Pigs: Toward the Discovery of Human Biomarkers for Liver Regeneration |
| Q33685829 | Circulating proteolytic products of carboxypeptidase N for early detection of breast cancer |
| Q34986725 | Clinical peptidomic analysis by a one-step direct transfer technology: its potential utility for monitoring of pathophysiological status in female reproductive system disorders. |
| Q38202166 | Colorectal cancer biomarker discovery and validation using LC-MS/MS-based proteomics in blood: truth or dare? |
| Q58746752 | Combined detection of IL-6 and IL-8 is beneficial to the diagnosis of early stage esophageal squamous cell cancer: a preliminary study based on the screening of serum markers using protein chips |
| Q40198410 | Comparative mass spectrometric and immunoassay-based proteome analysis in serum of Duchenne muscular dystrophy patients |
| Q43071119 | Comparison of nanotube-protein corona composition in cell culture media. |
| Q57808143 | Contribution of the plasma and lymph Degradome and Peptidome to the MHC Ligandome |
| Q36686826 | Conventional and proteomic technologies for the detection of early stage malignancies: markers for ovarian cancer |
| Q37610317 | Current advances in tumor proteomics and candidate biomarkers for hepatic cancer |
| Q36640047 | Current status and prospects of clinical proteomics studies on detection of colorectal cancer: hopes and fears |
| Q33545471 | Differential expression of proteomics models of colorectal cancer, colorectal benign disease and healthy controls |
| Q37369262 | Differential scanning calorimetry of blood plasma for clinical diagnosis and monitoring |
| Q35686503 | Effects of a Terrified-Sound Stress on Serum Proteomic Profiling in Mice |
| Q36562084 | Effects of preanalytical variables on peptide and protein measurements in human serum and plasma: implications for clinical proteomics |
| Q53556589 | Facile preparation of core-shell magnetic metal-organic framework nanospheres for the selective enrichment of endogenous peptides. |
| Q33764539 | Finding diabetic nephropathy biomarkers in the plasma peptidome by high-throughput magnetic bead processing and MALDI-TOF-MS analysis |
| Q37414647 | Follicular fluid biomarkers for human in vitro fertilization outcome: Proof of principle. |
| Q53153073 | Further investigation of a peptide extraction method with mesoporous silica using high-performance liquid chromatography coupled with tandem mass spectrometry. |
| Q39950457 | Future perspective for diagnosis in autoimmune diseases. |
| Q33579375 | High-throughput and targeted in-depth mass spectrometry-based approaches for biofluid profiling and biomarker discovery |
| Q38743204 | Identification of Hip BMD Loss and Fracture Risk Markers Through Population-Based Serum Proteomics. |
| Q35979222 | Identification of Serum Peptidome Signatures of Non-Small Cell Lung Cancer |
| Q64982716 | Improved phosphoproteomic analysis for phosphosignaling and active-kinome profiling in Matrigel-embedded spheroids and patient-derived organoids. |
| Q45979897 | Improved protocols for vibrational spectroscopic analysis of body fluids. |
| Q34005862 | Increased circulating cell signalling phosphoproteins in sera are useful for the detection of pancreatic cancer |
| Q34344991 | Inferring proteolytic processes from mass spectrometry time series data using degradation graphs |
| Q34248132 | Inferring serum proteolytic activity from LC-MS/MS data |
| Q42282520 | Intermediate and low abundant protein analysis of vitamin D deficient obese and non-obese subjects by MALDI-profiling. |
| Q38694933 | Low-Molecular-Weight Plasma Proteome Analysis Using Top-Down Mass Spectrometry |
| Q36147848 | MALDI-MS-Based Profiling of Serum Proteome: Detection of Changes Related to Progression of Cancer and Response to Anticancer Treatment. |
| Q33261717 | MALDI-TOF serum protein profiling for the detection of breast cancer |
| Q37201437 | Mass spectrometry for monitoring protease reactions |
| Q30985472 | Mass spectrometry-based analysis of therapy-related changes in serum proteome patterns of patients with early-stage breast cancer. |
| Q35238008 | Mass spectrometry-based serum and plasma peptidome profiling for prediction of treatment outcome in patients with solid malignancies |
| Q33481276 | Mass spectrometry-based serum proteome pattern analysis in molecular diagnostics of early stage breast cancer |
| Q34234274 | Nanodevices in diagnostics. |
| Q55518386 | Nanoparticle technology: Addressing the fundamental roadblocks to protein biomarker discovery. |
| Q34374324 | Peptidome analysis of cerebrospinal fluid by LC-MALDI MS |
| Q34804556 | Peptidomic Identification of Serum Peptides Diagnosing Preeclampsia |
| Q36950443 | Peptidomics analysis of human blood specimens for biomarker discovery |
| Q37481709 | Perspectives of targeted mass spectrometry for protein biomarker verification |
| Q36841871 | Plasma/serum proteomics: pre-analytical issues. |
| Q33499899 | Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling |
| Q36741325 | Principles of proteomics and its applications in cancer |
| Q45948712 | Protein biomarker druggability profiling. |
| Q35580549 | Proteomic Protease Substrate Profiling of tPA Treatment in Acute Ischemic Stroke Patients: A Step Toward Individualizing Thrombolytic Therapy at the Bedside |
| Q34395996 | Proteomic serum biomarkers and their potential application in cancer screening programs |
| Q37770437 | Proteomic strategies and challenges in tumor metastasis research. |
| Q34657835 | Proteomic technology for biomarker profiling in cancer: an update |
| Q36787244 | Proteomics in atherothrombosis: a future perspective |
| Q36841893 | Quantitation of target proteins and post-translational modifications in affinity-based proteomics approaches |
| Q37579913 | Recent advances in mass spectrometry-based peptidome analysis |
| Q33293388 | Reduced transthyretin expression in sera of lung cancer |
| Q47282466 | Screening the low molecular weight fraction of human serum using ATR-IR spectroscopy |
| Q38788924 | Selective expression of transthyretin in subtypes of lung cancer |
| Q33748762 | Serum Peptidome Profiling in Patients with Lung Cancer |
| Q33590076 | Serum albumin-bound proteomic signature for early detection and staging of hepatocarcinoma: sample variability and data classification |
| Q28743469 | Serum apolipoproteins C-I and C-III are reduced in stomach cancer patients: results from MALDI-based peptidome and immuno-based clinical assays |
| Q33321301 | Serum biomarker profile associated with high bone turnover and BMD in postmenopausal women |
| Q36582422 | Serum biomarkers identification by mass spectrometry in high-mortality tumors |
| Q34333169 | Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia |
| Q33955495 | Serum peptidome profiling in patients with gastric cancer |
| Q49720857 | Serum proteomic profiling for autism using magnetic bead-assisted matrix-assisted laser desorption ionization time-of-flight mass spectrometry: a pilot study |
| Q33943422 | Setup for human sera MALDI profiling: the case of rhEPO treatment |
| Q33269937 | Sherlock Holmes and the proteome--a detective story |
| Q34279102 | Soluble plasma HLA peptidome as a potential source for cancer biomarkers |
| Q34268788 | Specific Investigation of Sample Handling Effects on Protease Activities and Absolute Serum Concentrations of Various Putative Peptidome Cancer Biomarkers |
| Q47180758 | Strategies for Characterization of Low-Abundant Intact or Truncated Low-Molecular-Weight Proteins From Human Plasma. |
| Q33764263 | Surface engineering on mesoporous silica chips for enriching low molecular weight phosphorylated proteins |
| Q37453847 | Targeted proteomic strategy for clinical biomarker discovery |
| Q28085015 | Targeted proteomics for biomarker discovery and validation of hepatocellular carcinoma in hepatitis C infected patients |
| Q44924621 | The blood peptidome: a higher dimension of information content for cancer biomarker discovery |
| Q47587382 | The potential of serum proteomics for detection of cancer: promise or only hope? |
| Q37818317 | Tissue and serum proteomic profiling for diagnostic and prognostic bladder cancer biomarkers. |
| Q33257826 | When does a fingerprint constitute a diagnostic? |
Search more.